A group of scientists at the Burnham Institute for Medical Research in La Jolla, CA, analyzed the mechanism by which certain cellular signaling cues cause epigenetic modifications when released within the regenerative microenvironment, thus controlling the expression of genes that regulate growth and differentiation of muscle stem cells that repair injured muscle.
In a recent publication in Molecular Cell, the scientific group, led by Pier Lorenzo Puri, MD, Ph.D., shows how two signaling pathways, PI3K/AKT and p38, work together to assemble components of the protein complexes responsible for muscle-specific transcription, and how each pathway is responsible for a distinct step in the transcription process. Additionally, the team was able to pharmacologically separate these two steps, showing that selective interference with either cascade leads to incomplete assembly of protein complexes, thus preventing muscle-specific gene expression. The results point to possible pharmacological avenues for selective control of gene expression in adult muscle stem cells that may have therapeutic potential in regenerative medicine.
Dr. Puri is an Assistant Professor in the Tumor Development Program at the Burnham Institute for Medical Research. The study was conducted in collaboration with the Dulbecco Telethon Institute at Fondazione Santa Lucia/EBRI; Department of Surgery, University of Virginia, Charlottesville; Molecular Oncology Research Institute, Tufts-New England Medical Center; and The Whittier Institute.
About Burnham Institute for Medical Research
Burnham Institute for Medical Research conducts world-class collaborative research dedicated to finding cures for human disease, improving quality of life, and thus creating a legacy for its employees, donors, and community. The Institute is headquartered in La Jolla, CA where it was established as a nonprofit, public benefit corporation in 1976 and is now home to three major centers: a National Cancer Institute-designated Cancer Center; the Del E. Webb Center for Neurosciences, Aging and Stem Cell Research; and the Infectious and Inflammatory Disease Center. In 2006, Burnham established a center for bionanotechnology research at the University of California, Santa Barbara. Burnham is currently establishing a campus at Lake Nona in Orlando, Florida that will focus on diabetes and obesity research and will expand the Institute’s drug discovery capabilities. Today, Burnham employs more than 800 people and ranks consistently among the world’s top 25 organizations for its research impact and among the top four research institutes nationally for NIH grant funding.
Andrea Moser | EurekAlert!
Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz
Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB
28.04.2017 | Event News
20.04.2017 | Event News
18.04.2017 | Event News
28.04.2017 | Medical Engineering
28.04.2017 | Earth Sciences
28.04.2017 | Life Sciences